MedTrace Logo

Trikafta Exercise Study in Cystic Fibrosis

NCT05279040 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-05-18

No results posted yet for this study

Summary

Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.

Conditions

Interventions

DRUG

Trikafta

Elexacaftor/Tezacaftor/Ivacaftor combination therapy

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jordan A Guenette, PhD · University of British Columbia

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-10
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05279040 on ClinicalTrials.gov